<DOC>
	<DOCNO>NCT02917577</DOCNO>
	<brief_summary>The study prospective , single centre , double-blinded randomize controlled trial whose goal compare immune response population immunosuppressed pediatric rheumatology patient immunosuppressive medication two different dos Hepatitis A vaccine . The objective ( ) confirm adolescent , like adult counterpart , reduce immune response hepatitis A vaccine , ( b ) compare immunogenicity two different dose option vaccine age group one two dos . A total 60 adolescent age 12 - 15 year confirm chronic rheumatologic condition treat immunosuppressive therapy recruit Rheumatology Clinic Alberta Children 's Hospital ( ACH ) . Those found immunity hepatitis A enrol . Informed , write consent obtain parent guardian subject , assent obtain study subject . Subjects randomly assign two dos either Avaxim Pediatric® Avaxim ® ( adult ) vaccine ( Sanofi Pasteur Canada ) , six month apart , hepatitis A titre do baseline one month dose . Both formulation license age group .</brief_summary>
	<brief_title>Hepatitis A Vaccine Dosing Regimens Among Pediatric Rheumatology Patients Immunosuppressive Therapy</brief_title>
	<detailed_description>This prospective , single centre , randomize , control trial compare immune response two dos license Hepatitis A vaccine child . Subjects receive 2 dos ( 0.5 mL ) assign study vaccine ( Avaxim Pediatric® Avaxim ® ( adult ) vaccine ) . One lot vaccine formulation study . All subject provide safety observation use diary sequential blood sample obtain measure serologic/immunologic response . The study population include 60 subject confirm rheumatologic condition immunosuppressive medication , male female , age range 12 - 15 year . The maximum age enrollment 15 year 5 month , allow 7 month complete 2 dos vaccine age 16 years.Both vaccine formulation use trial license use Canada age range subject study .</detailed_description>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Autoimmune Diseases</mesh_term>
	<mesh_term>Rheumatic Diseases</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Immunosuppressive Agents</mesh_term>
	<criteria>Written inform consent provide subject parent legal guardian . Written inform assent participant . Subjects whose parent investigator believe comply requirement protocol ( i.e . return followup visit , record safety observation , able converse study personnel contactable telephone ) . Age 12 year 15 year 5 month Confirmed chronic rheumatologic condition Maintained immunosuppressive medication exception pulse steroid Systemic hypersensitivity Hepatitis A vaccine component neomycin , 2phenoxyethanol , formaldehyde , aluminum hydroxide , Medium 199 Hanks , Polysorbate 80 . Thrombocytopenia bleed disorder contraindicates IM injection blood collection . Receipt blood bloodderived product ( include IVIG ) within past 3 month . Previous laboratoryconfirmed infection Hepatitis A Previous vaccination Hepatitis A vaccine The following condition temporary selflimiting exclusion subject vaccinated condition resolve exclusion criterion exist : Current febrile illness oral temperature ≥ 38.5 °C ( equivalent route ) moderate severe illness within 24 hour study vaccine administration Receipt Hepatitis B vaccine within 28 day plan study vaccine dos . When Twinrix® study , response Hepatitis B amplify presence Hepatitis A . It unknown whether reverse also true . Routine childhood vaccine ( except MMR Varicella ) must separate study vaccination least 7 day .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>15 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>